Free Trial
→ Trump Makes Major Crypto Announcement (From Crypto 101 Media) (Ad) Buy CGEM Stock  Free CGEM Stock Alerts

Cullinan Therapeutics (CGEM) Financials

Cullinan Therapeutics logo
$8.79 +0.27 (+3.17%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$8.78 0.00 (-0.06%)
As of 05/2/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Cullinan Therapeutics

Annual Income Statements for Cullinan Therapeutics

This table shows Cullinan Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 111 -153 -167
Consolidated Net Income / (Loss)		 109 -155 -168
Net Income / (Loss) Continuing Operations		 109 -155 -168
Total Pre-Tax Income 		151 -169 -167
Total Operating Income		 145 -191 -197
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 -145 191 197
Selling, General & Admin Expense		 40 42 54
Research & Development Expense		 92 148 143
Total Other Income / (Expense), net		 6.67 22 29
Interest & Investment Income		 6.61 22 30
Other Income / (Expense), net		 0.06 0.24 -0.20
Income Tax Expense		 42 -14 0.12
Net Income / (Loss) Attributable to Noncontrolling Interest		 -2.02 -1.94 -0.19
Basic Earnings per Share		 $2.46 ($35.33) $0.00
Weighted Average Basic Shares Outstanding		 45.16M 42.16M 0.00
Diluted Earnings per Share		 $2.38 ($35.33) $0.00
Weighted Average Diluted Shares Outstanding		 46.64M 42.16M 0.00
Weighted Average Basic & Diluted Shares Outstanding		 39.33M 43.07M 58.51M

Quarterly Income Statements for Cullinan Therapeutics

This table shows Cullinan Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -25 -27 -58 -32 -39 -24 -37 -42 -41 -48
Consolidated Net Income / (Loss)		 -25 -27 -58 -32 -39 -26 -37 -42 -41 -48
Net Income / (Loss) Continuing Operations		 -25 -27 -58 -32 -39 -26 -37 -42 -41 -48
Total Pre-Tax Income 		-27 -29 -58 -32 -39 -40 -37 -42 -41 -48
Total Operating Income		 -30 -33 -63 -38 -45 -45 -43 -50 -49 -55
Total Operating Expenses		 30 33 63 38 45 45 43 50 49 55
Selling, General & Admin Expense		 10 11 11 10 11 11 12 14 13 15
Research & Development Expense		 20 21 52 27 34 35 31 36 36 40
Total Other Income / (Expense), net		 2.35 3.66 4.62 5.39 6.06 5.80 5.65 8.00 8.30 7.52
Interest & Investment Income		 2.35 3.36 4.51 5.32 5.88 5.92 5.69 8.07 8.38 7.51
Other Income / (Expense), net		 0.00 0.30 0.11 0.07 0.18 -0.12 -0.04 -0.07 -0.09 0.01
Basic Earnings per Share		 ($0.54) ($0.63) ($1.42) ($0.82) ($0.91) ($32.18) ($0.86) ($0.75) ($0.69) $2.30
Weighted Average Basic Shares Outstanding		 45.61M 45.16M 40.68M 39.95M 42.73M 42.16M 43.01M 55.05M 58.34M 0.00
Diluted Earnings per Share		 ($0.54) ($0.58) ($1.42) ($0.82) ($0.91) ($32.18) ($0.86) ($0.75) ($0.69) $2.30
Weighted Average Diluted Shares Outstanding		 45.61M 46.64M 40.68M 39.95M 42.73M 42.16M 43.01M 55.05M 58.34M 0.00
Weighted Average Basic & Diluted Shares Outstanding		 45.77M 39.33M 40.68M 42.73M 42.78M 43.07M 57.63M 57.98M 58.23M 58.51M

Annual Cash Flow Statements for Cullinan Therapeutics

This table details how cash moves in and out of Cullinan Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 96 -58 -15
Net Cash From Operating Activities		 -127 -134 -145
Net Cash From Continuing Operating Activities		 -127 -134 -145
Net Income / (Loss) Continuing Operations		 109 -155 -168
Consolidated Net Income / (Loss)		 109 -155 -168
Depreciation Expense		 0.09 0.31 0.31
Amortization Expense		 1.29 -10 -15
Non-Cash Adjustments To Reconcile Net Income		 -248 31 38
Changes in Operating Assets and Liabilities, net		 11 -0.34 -0.39
Net Cash From Investing Activities		 249 36 -136
Net Cash From Continuing Investing Activities		 249 36 -136
Purchase of Property, Plant & Equipment		 -1.13 -0.21 0.00
Purchase of Investments		 -378 -373 -721
Sale and/or Maturity of Investments		 353 409 585
Net Cash From Financing Activities		 -26 41 266
Net Cash From Continuing Financing Activities		 -26 41 266
Repayment of Debt		 -2.20 0.00 0.00
Payment of Dividends		 -33 0.00 -4.45
Issuance of Preferred Equity		 2.38 1.83 0.00
Issuance of Common Equity		 6.02 39 271
Other Financing Activities, net		 1.15 0.00 0.00
Cash Income Taxes Paid		 38 -4.43 -2.27

Quarterly Cash Flow Statements for Cullinan Therapeutics

This table details how cash moves in and out of Cullinan Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -111 -87 -34 20 -77 34 -24 41 -13 -19
Net Cash From Operating Activities		 -54 -25 -51 -31 -34 -18 -38 -36 -34 -37
Net Cash From Continuing Operating Activities		 -54 -25 -51 -31 -34 -18 -38 -36 -34 -37
Net Income / (Loss) Continuing Operations		 -25 -27 -58 -32 -39 -26 -37 -42 -41 -48
Consolidated Net Income / (Loss)		 -25 -27 -58 -32 -39 -26 -37 -42 -41 -48
Depreciation Expense		 0.01 0.06 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08
Amortization Expense		 0.16 -0.60 -1.37 - - -3.62 -3.31 - - -3.51
Non-Cash Adjustments To Reconcile Net Income		 5.26 7.69 7.26 4.40 12 7.65 8.23 3.50 16 9.63
Changes in Operating Assets and Liabilities, net		 -35 -5.01 1.18 -4.65 -0.18 3.31 -5.90 -1.15 1.84 4.82
Net Cash From Investing Activities		 -58 -29 15 12 -43 51 13 -185 20 16
Net Cash From Continuing Investing Activities		 -58 -29 15 12 -43 51 13 -185 20 16
Purchase of Investments		 -124 -160 -89 -81 -137 -66 -131 -325 -97 -168
Sale and/or Maturity of Investments		 61 133 104 94 94 117 144 140 117 184
Net Cash From Financing Activities		 1.43 -33 1.79 39 0.11 0.25 1.09 262 1.33 1.58
Net Cash From Continuing Financing Activities		 1.43 -33 1.79 39 0.11 0.25 1.09 262 1.33 1.58
Issuance of Common Equity		 1.43 0.19 -0.04 0.21 0.11 39 1.09 3.34 1.98 264
Other Financing Activities, net		 - - - - - -38 - - - -263

Annual Balance Sheets for Cullinan Therapeutics

This table presents Cullinan Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 561 484 622
Total Current Assets		 474 480 415
Cash & Equivalents		 156 98 83
Short-Term Investments		 311 369 316
Prepaid Expenses		 7.18 13 16
Plant, Property, & Equipment, net		 1.17 0.99 0.68
Total Noncurrent Assets		 85 3.00 206
Long-Term Investments		 81 0.00 204
Other Noncurrent Operating Assets		 4.59 3.00 2.03
Total Liabilities & Shareholders' Equity		 561 484 622
Total Liabilities		 26 30 31
Total Current Liabilities		 22 28 31
Accounts Payable		 2.66 2.49 1.68
Accrued Expenses		 14 24 28
Other Current Liabilities		 1.42 1.44 1.30
Total Noncurrent Liabilities		 3.59 2.15 0.85
Other Noncurrent Operating Liabilities		 3.59 2.15 0.85
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 535 454 590
Total Preferred & Common Equity		 535 454 590
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 535 454 590
Common Stock		 585 655 959
Retained Earnings		 -48 -201 -368
Accumulated Other Comprehensive Income / (Loss)		 -2.60 -0.13 -0.13
Noncontrolling Interest		 0.00 0.19 0.00

Quarterly Balance Sheets for Cullinan Therapeutics

This table presents Cullinan Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 617 515 522 495 449 681 653
Total Current Assets		 582 399 498 477 446 678 592
Cash & Equivalents		 243 122 142 65 74 115 102
Short-Term Investments		 333 269 350 402 359 547 476
Prepaid Expenses		 6.12 8.33 6.44 10 13 15 14
Plant, Property, & Equipment, net		 0.79 1.24 1.16 1.07 0.91 0.84 0.76
Total Noncurrent Assets		 34 115 23 17 2.80 2.58 60
Long-Term Investments		 29 110 19 14 0.00 0.00 58
Other Noncurrent Operating Assets		 4.96 4.28 3.96 3.38 2.80 2.58 2.48
Total Liabilities & Shareholders' Equity		 617 515 522 495 449 681 653
Total Liabilities		 31 29 22 26 24 25 25
Total Current Liabilities		 27 26 20 23 22 23 24
Accounts Payable		 1.52 2.03 2.49 0.95 3.71 1.56 2.12
Accrued Expenses		 14 18 16 21 17 21 21
Other Current Liabilities		 0.70 1.55 1.65 1.55 1.33 1.22 1.26
Total Noncurrent Liabilities		 3.99 3.17 2.73 2.45 1.84 1.52 1.19
Noncurrent Deferred Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 3.99 3.17 2.73 2.45 1.84 1.52 1.19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 586 486 500 469 426 656 628
Total Preferred & Common Equity		 586 486 500 469 426 656 628
Preferred Stock		 - - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 586 486 500 469 426 656 628
Common Stock		 611 593 639 647 664 937 947
Retained Earnings		 -21 -106 -138 -177 -238 -280 -321
Accumulated Other Comprehensive Income / (Loss)		 -3.93 -1.24 -1.63 -1.05 -0.33 -0.48 0.97
Noncontrolling Interest		 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics and Ratios for Cullinan Therapeutics

This table displays calculated financial ratios and metrics derived from Cullinan Therapeutics' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 -100.00% 0.00% 0.00%
EBITDA Growth		 315.13% -237.38% -5.77%
EBIT Growth		 312.92% -231.89% -3.28%
NOPAT Growth		 319.44% -228.15% -3.05%
Net Income Growth		 261.81% -242.04% -8.04%
EPS Growth		 0.00% -1,584.45% 100.00%
Operating Cash Flow Growth		 -191.63% -6.01% -8.21%
Free Cash Flow Firm Growth		 315.58% -219.36% -3.13%
Invested Capital Growth		 -139.48% -0.21% 0.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 2.36% -8.84% -4.60%
EBIT Q/Q Growth		 1.42% -7.49% -5.03%
NOPAT Q/Q Growth		 -26.96% -7.23% -5.10%
Net Income Q/Q Growth		 6.97% 0.97% -15.18%
EPS Q/Q Growth		 0.00% -847.19% 100.00%
Operating Cash Flow Q/Q Growth		 -8.40% 4.86% -14.59%
Free Cash Flow Firm Q/Q Growth		 -30.94% -0.68% -2.84%
Invested Capital Q/Q Growth		 31.67% -18.05% -59.78%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 72.16% 91.65% 100.07%
Interest Burden Percent		 104.57% 88.67% 84.95%
Effective Tax Rate		 27.84% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 22.74% -31.37% -32.10%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 22.73% -31.36% -32.09%
Return on Equity Simple (ROE_SIMPLE)		 20.41% -34.19% -28.39%
Net Operating Profit after Tax (NOPAT)		 104 -134 -138
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.98% -4.20% -5.55%
Return On Investment Capital (ROIC_SIMPLE)		 - -29.47% -23.35%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 145 -191 -197
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 146 -201 -212
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.90 0.96 1.20
Price to Tangible Book Value (P/TBV)		 0.90 0.96 1.20
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 4.34 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 23.03% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.03
Leverage Ratio		 1.04 1.06 1.06
Compound Leverage Factor		 1.09 0.94 0.90
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.04% 0.00%
Common Equity to Total Capital		 100.00% 99.96% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 12.80 7.87 12.38
Noncontrolling Interest Sharing Ratio		 0.04% 0.02% 0.02%
Liquidity Ratios		 - - -
Current Ratio		 21.09 17.07 13.53
Quick Ratio		 20.77 16.60 13.02
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 112 -134 -138
Operating Cash Flow to CapEx		 -12,155.85% -64,555.29% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -13 -13 -13
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -7.66 -0.03 0.08
Enterprise Value (EV)		 -65 -31 106
Market Capitalization		 483 436 709
Book Value per Share		 $11.69 $10.61 $10.14
Tangible Book Value per Share		 $11.69 $10.61 $10.14
Total Capital		 535 454 590
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -548 -467 -603
Capital Expenditures (CapEx)		 1.04 0.21 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -15 -15
Debt-free Net Working Capital (DFNWC)		 452 452 384
Net Working Capital (NWC)		 452 452 384
Net Nonoperating Expense (NNE)		 -4.81 21 30
Net Nonoperating Obligations (NNO)		 -548 -467 -603
Total Depreciation and Amortization (D&A)		 1.39 -9.84 -15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $2.46 ($3.69) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 45.16M 41.55M 0.00
Adjusted Diluted Earnings per Share		 $2.38 ($3.69) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 46.64M 41.55M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 39.33M 43.07M 58.51M
Normalized Net Operating Profit after Tax (NOPAT)		 -95 -134 -138
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 30.48% 0.00% -2.65%
Augmented Payout Ratio		 30.48% 0.00% -2.65%

Quarterly Metrics and Ratios for Cullinan Therapeutics

This table displays calculated financial ratios and metrics derived from Cullinan Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -69.74% 4.31% -101.74% -115.59% -51.97% -49.60% 27.66% -33.55% -8.64% -18.98%
EBIT Growth		 -61.97% 5.92% -91.84% -115.68% -51.39% -41.14% 31.31% -33.47% -8.61% -20.70%
NOPAT Growth		 -61.99% 5.06% -92.17% -115.15% -52.00% -39.49% 31.50% -33.03% -7.98% -21.02%
Net Income Growth		 -36.32% 20.81% -350.99% -118.51% -57.42% 5.63% 35.78% -30.47% -3.51% -86.39%
EPS Growth		 -35.00% 0.00% -425.93% -121.75% -68.52% -5,448.28% 39.44% 8.54% 24.18% 107.15%
Operating Cash Flow Growth		 -415.15% -64.68% -132.78% -21.97% 37.19% 27.43% 25.00% -17.05% 0.01% -102.01%
Free Cash Flow Firm Growth		 88.43% 46.67% 50.80% -128.84% -2,551.35% -109.71% -112.46% 39.10% 6.50% -21.39%
Invested Capital Growth		 -19,337.00% -139.48% -248.43% 78.10% 42.00% -0.21% 52.59% 42.20% 26.58% 0.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -112.32% -10.98% -94.66% 41.43% -20.10% -9.25% 5.87% -8.13% 2.31% -19.66%
EBIT Q/Q Growth		 -112.43% -8.55% -93.90% 40.09% -20.05% -1.20% 5.63% -16.42% 2.31% -12.46%
NOPAT Q/Q Growth		 -111.99% -9.55% -92.46% 40.08% -20.31% -0.53% 5.49% -16.37% 2.34% -12.68%
Net Income Q/Q Growth		 -114.30% -8.83% -114.64% 44.59% -21.63% 34.76% -46.07% -12.55% 3.49% -17.47%
EPS Q/Q Growth		 -114.32% -7.41% -144.83% 42.25% -10.98% -3,436.26% -59.26% 12.79% 8.00% 433.33%
Operating Cash Flow Q/Q Growth		 -113.82% 54.04% -104.13% 39.20% -10.11% 46.89% -110.95% 5.11% 5.93% -7.28%
Free Cash Flow Firm Q/Q Growth		 -100.66% -911.85% -18.65% -261.30% 38.87% 19.97% -20.20% -3.56% 6.15% -3.91%
Invested Capital Q/Q Growth		 61.18% 31.67% -17.86% 29.94% -2.79% -18.05% 44.23% 14.59% -30.57% -59.78%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 90.80% 93.58% 100.00% 100.00% 100.00% 64.41% 100.00% 100.00% 100.00% 100.25%
Interest Burden Percent		 92.10% 89.59% 92.80% 85.82% 86.95% 87.02% 86.77% 83.89% 82.87% 86.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 19.79% 22.74% 14.13% -25.78% -29.69% -31.37% -29.47% -24.94% -26.53% -32.10%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 19.75% 22.73% 14.12% -25.78% -29.69% -31.36% -29.47% -24.94% -26.53% -32.09%
Return on Equity Simple (ROE_SIMPLE)		 17.42% 0.00% 13.17% -28.49% -33.41% 0.00% -31.55% -21.96% -23.17% 0.00%
Net Operating Profit after Tax (NOPAT)		 -21 -23 -44 -26 -32 -32 -30 -35 -34 -39
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.77% -0.87% -3.12% -1.01% -1.38% 1.24% -1.55% -1.20% -1.14% -1.70%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -7.01% - - - -6.53%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -30 -32 -63 -38 -45 -46 -43 -50 -49 -55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -30 -33 -64 -37 -45 -49 -46 -50 -49 -58
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.00 0.90 0.83 0.85 0.82 0.96 1.72 1.53 1.55 1.20
Price to Tangible Book Value (P/TBV)		 1.00 0.90 0.83 0.85 0.82 0.96 1.72 1.53 1.55 1.20
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 5.54 4.34 6.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 18.04% 23.03% 16.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.01 -1.05 -1.03 -1.03 -1.03 -1.01 -1.02 -1.03
Leverage Ratio		 1.04 1.04 1.05 1.08 1.05 1.06 1.06 1.04 1.05 1.06
Compound Leverage Factor		 0.96 0.93 0.98 0.92 0.92 0.92 0.92 0.87 0.87 0.91
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.04% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 99.96% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 12.15 11.76 8.41 11.83 9.26 8.86 18.60 24.46 23.04 13.13
Noncontrolling Interest Sharing Ratio		 0.20% 0.04% 0.08% 0.01% 0.00% 0.02% 0.00% 0.00% 0.00% 0.02%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 21.47 21.09 15.25 25.32 20.33 17.07 20.33 28.87 24.46 13.53
Quick Ratio		 21.24 20.77 14.93 24.99 19.90 16.60 19.75 28.22 23.88 13.02
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.50 -15 -18 -65 -40 -32 -38 -40 -37 -39
Operating Cash Flow to CapEx		 -21,654.58% -2,832.54% -32,073.58% -63,277.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -19 -13 -15 -11 -11 -13 -7.35 -6.27 -8.19 -13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -19 -7.66 -26 39 8.08 -0.03 8.15 4.58 2.97 0.08
Enterprise Value (EV)		 -21 -65 -99 -87 -93 -31 301 343 334 106
Market Capitalization		 585 483 402 424 387 436 734 1,005 971 709
Book Value per Share		 $12.85 $11.69 $12.35 $12.69 $10.97 $10.61 $9.88 $11.39 $10.83 $10.14
Tangible Book Value per Share		 $12.85 $11.69 $12.35 $12.69 $10.97 $10.61 $9.88 $11.39 $10.83 $10.14
Total Capital		 586 535 486 500 469 454 426 656 628 590
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -605 -548 -501 -510 -480 -467 -433 -662 -636 -603
Capital Expenditures (CapEx)		 0.25 0.88 0.16 0.05 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -21 -15 -18 -13 -13 -15 -9.22 -8.17 -10 -15
Debt-free Net Working Capital (DFNWC)		 555 452 373 479 453 452 424 654 568 384
Net Working Capital (NWC)		 555 452 373 479 453 452 424 654 568 384
Net Nonoperating Expense (NNE)		 4.05 4.26 14 5.89 7.51 -6.28 7.25 7.01 6.36 9.11
Net Nonoperating Obligations (NNO)		 -605 -548 -501 -510 -480 -467 -433 -662 -636 -603
Total Depreciation and Amortization (D&A)		 0.17 -0.54 -1.30 0.08 0.08 -3.54 -3.23 0.08 0.08 -3.43
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.54) ($0.63) $0.00 ($0.82) ($0.91) ($32.18) ($0.86) ($0.75) ($0.69) $2.30
Adjusted Weighted Average Basic Shares Outstanding		 45.61M 45.16M 40.68M 39.95M 42.73M 42.16M 43.01M 55.05M 58.34M 0.00
Adjusted Diluted Earnings per Share		 ($0.54) ($0.58) $0.00 ($0.82) ($0.91) ($32.18) ($0.86) ($0.75) ($0.69) $2.30
Adjusted Weighted Average Diluted Shares Outstanding		 45.61M 46.64M 40.68M 39.95M 42.73M 42.16M 43.01M 55.05M 58.34M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 45.77M 39.33M 40.68M 42.73M 42.78M 43.07M 57.63M 57.98M 58.23M 58.51M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -23 -44 -26 -32 -32 -30 -35 -34 -39
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 30.48% 0.00% 0.00% 0.00% 0.00% 0.00% -2.63% -3.06% -2.65%
Augmented Payout Ratio		 0.00% 30.48% 0.00% 0.00% 0.00% 0.00% 0.00% -2.63% -3.06% -2.65%

Frequently Asked Questions About Cullinan Therapeutics' Financials

When does Cullinan Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Cullinan Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cullinan Therapeutics' net income changed over the last 2 years?

Cullinan Therapeutics' net income appears to be on an upward trend, with a most recent value of -$167.58 million in 2024, falling from $109.20 million in 2022. The previous period was -$155.10 million in 2023. See Cullinan Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Cullinan Therapeutics's operating income?
Cullinan Therapeutics's total operating income in 2024 was -$196.92 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $196.92 million
How has Cullinan Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Cullinan Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Cullinan Therapeutics have?

Cullinan Therapeutics' total liabilities were at $31.50 million at the end of 2024, a 4.0% increase from 2023, and a 20.7% increase since 2022.

How much cash does Cullinan Therapeutics have?

In the past 2 years, Cullinan Therapeutics' cash and equivalents has ranged from $83.01 million in 2024 to $156.15 million in 2022, and is currently $83.01 million as of their latest financial filing in 2024.

How has Cullinan Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Cullinan Therapeutics' book value per share changed from 11.69 in 2022 to 10.14 in 2024, a change of -13.3%.


Related Companies

This page (NASDAQ:CGEM) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...
Altimetry | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored